Prestige Consumer Healthcare's stock experienced a significant after-hours plunge of 6.39% on Wednesday following the release of its fiscal fourth-quarter and full-year results.

The consumer healthcare company reported adjusted earnings of $1.23 per share for the quarter, missing the analyst consensus estimate of $1.39. Quarterly revenue of $281.6 million also fell short of the expected $293.6 million. For the full fiscal year 2026, revenue declined 4.3% to $1.09 billion, while earnings per share dropped to $3.91 from $4.29 a year earlier.

The company cited several factors for the weaker performance, including supply constraints in its Eye & Ear Care category that limited its ability to meet demand for Clear Eyes products. International segment revenue was hurt by shipping disruptions in the Middle East, and accelerated order timing in the prior year created a headwind for the current quarter. Furthermore, the company's fiscal 2027 guidance for revenue and adjusted earnings per share came in below analyst expectations.